Cefiderocol May Be Effective In Treating Multidrug-Resistant Infections In Patients Who Are Immunocompromised, Study Finds

Infectious Disease Advisor (3/5, Basilio) reports a study suggests that “cefiderocol may be effective against multidrug-resistant (MDR) infections in immunocompromised populations, but its use requires careful monitoring due to high associated rates of relapse and resistance acquisition.” Researchers concluded, “Cefiderocol (FDC) is a recent antibiotic, combining a cephalosporin and a catechol-type siderophore allowing bacterial internalization via multiple iron transporters.” In regards to its use, “the present study shows that clinical success rates in the immunocompromised setting are not different that of the rates previously reported in pivotal randomized control trials,” researchers said. The study was published in the Journal of Infection.